Regulatory Pressure Mounts for Telehealth Firm Hims & Hers

The telehealth company Hims & Hers finds itself navigating a significant regulatory challenge following action by the U.S. Food and Drug Administration (FDA). This development casts a shadow over the firm’s otherwise impressive growth trajectory, raising questions about the impact on its future performance.

Strong Quarterly Performance Amidst Headwinds

Despite the emerging regulatory concerns, the company’s operational results for the second quarter of 2025 were exceptionally strong. The financial and subscriber metrics underscore its rapid expansion:

• Revenue reached $544.8 million, representing a substantial 73% year-over-year increase.
• The subscriber base grew to over 2.4 million, a 31% jump compared to the previous year.
• Net income was reported at $42.5 million.
• Management has reaffirmed its full-year revenue guidance of between $2.3 and $2.4 billion.

FDA Warning Letter Targets Marketing Practices

The situation escalated on September 9th when the FDA issued a formal warning letter to the company. The communication centered on the marketing of compounded semaglutide products, which are a key offering in Hims & Hers’s lucrative weight-loss segment. The agency alleged that statements on the company’s website were “false or misleading.”

A primary point of contention is the alleged portrayal of non-FDA-approved, compounded medications as being equivalent to their approved counterparts. News of the warning became public on September 16th, triggering an immediate and sharp decline in the company’s share price. Hims & Hers now has a 15-working-day deadline to outline corrective actions to the regulator.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Insider Trading Activity Adds to Investor Anxiety

Compounding the regulatory pressure, recent transactions by company executives have drawn investor scrutiny. Chief Financial Officer Oluyemi Okupe sold 145,000 shares on September 15th. Furthermore, a separate filing on September 22nd revealed that another insider plans to divest nearly 155,000 shares. The timing of these sales, coinciding with the regulatory turbulence, has contributed to market unease.

Wall Street’s Cautious Stance

The investment community appears divided in its assessment. While some firms, such as Canaccord Genuity, maintain a bullish outlook with a price target of $68, a more cautious tone prevails across the broader analyst spectrum. The consensus rating has shifted noticeably, with most experts now advising a “Hold” position—a significant change from the previously dominant “Buy” recommendations.

The critical uncertainty for investors is whether the company’s robust growth can outweigh the potential financial and reputational damage from the FDA’s intervention.